Abstract
EMBO J 30 13, 2719–2733 (2011); published online May 20 2011 Androgen signalling via the androgen receptor plays a critical role in prostate cancer development and is the primary drug target for prostate cancer therapy. However, given the frequent development of resistance to current therapies in many tumours, there is a great need for the identification of additional factors that could be exploited as drug targets. In this issue of The EMBO Journal, Massie et al (2011) have employed an integrated approach to reveal a role of androgen signalling in regulating central metabolism and molecular biosynthesis in prostate cancers. This study highlights how integrating various -omics data and combining these with clinical observations can bring new dimensions to our understanding of important clinical challenges and identification of novel drug targets.